Shaheen, Collins Issue Joint Statement On Novo Nordisk's Decision To Reduce Insulin Prices
March 15, 2023
March 15, 2023
WASHINGTON, March 15 -- Sen. Jeanne Shaheen, D-New Hampshire, issued the following news release:
U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following statement in response to drug maker Novo Nordisk's announcement that it will cut the list prices for its commonly prescribed insulin medication by 75 percent. Shaheen and Collins have long led action in the U.S. Senate to reduce insulin prices and spearhead the bipa . . .
U.S. Senators Jeanne Shaheen (D-NH) and Susan Collins (R-ME), co-chairs of the Senate Diabetes Caucus, issued the following statement in response to drug maker Novo Nordisk's announcement that it will cut the list prices for its commonly prescribed insulin medication by 75 percent. Shaheen and Collins have long led action in the U.S. Senate to reduce insulin prices and spearhead the bipa . . .